{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:33:14Z","timestamp":1760189594394},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00520-018-4052-1","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T21:41:59Z","timestamp":1517521319000},"page":"2247-2250","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ixazomib-induced cutaneous necrotizing vasculitis"],"prefix":"10.1007","volume":"26","author":[{"given":"A.","family":"Alloo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. R.","family":"Granter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. M.","family":"Jadeja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. R.","family":"LeBoeuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"issue":"5","key":"4052_CR1","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","volume":"70","author":"E Kupperman","year":"2010","unstructured":"Kupperman E, Lee EC, Cao Y et al (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70(5):1970\u20131980","journal-title":"Cancer Res"},{"issue":"24","key":"4052_CR2","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMicm041166","volume":"352","author":"MJ Agterof","year":"2005","unstructured":"Agterof MJ, Biesma DH (2005) Images in clinical Medicine. Bortezomib-induced skin lesions. N Engl J Med 352(24):2534","journal-title":"N Engl J Med"},{"issue":"3","key":"4052_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2437.x","volume":"76","author":"CK Min","year":"2006","unstructured":"Min CK, Lee S, Kim YJ (2006) Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. Eur J Haematol 76(3):265\u2013268","journal-title":"Eur J Haematol"},{"issue":"4","key":"4052_CR4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1365-2133.2007.08073.x","volume":"157","author":"X Garcia-Navarro","year":"2007","unstructured":"Garcia-Navarro X, Puig L, Fernandez-Figueras MT, Dalmau J, Roe E, Alomar A (2007) Bortezomib-associated cutaneous vasculitis. Br J Dermatol 157(4):799\u2013801. \n                    https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08073.x","journal-title":"Br J Dermatol"},{"issue":"13","key":"4052_CR5","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","volume":"15","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG (2014) Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol 15(13):1503\u20131512. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(14)71125-8","journal-title":"Lancet Oncol"},{"issue":"3","key":"4052_CR6","first-page":"1","volume":"58","author":"JM Loree","year":"2016","unstructured":"Loree JM, Cai E, Sheffield BS et al (2016) Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma. Leuk Lymphoma 58(3):1\u20134","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"4052_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40265-016-0548-5","volume":"76","author":"M Shirley","year":"2016","unstructured":"Shirley M (2016) Ixazomib: first global approval. Drugs 76(3):405\u2013411. \n                    https:\/\/doi.org\/10.1007\/s40265-016-0548-5","journal-title":"Drugs"},{"issue":"2","key":"4052_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.beha.2016.08.020","volume":"29","author":"A Paulus","year":"2016","unstructured":"Paulus A, Ailawadhi S, Chanan-Khan A (2016) Novel therapeutic targets in Waldenstrom macroglobulinemia. Best Pract Res Clin Haematol 29(2):216\u2013228. \n                    https:\/\/doi.org\/10.1016\/j.beha.2016.08.020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"4052_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/ph10020040","volume":"10","author":"S Chhabra","year":"2017","unstructured":"Chhabra S (2017) Novel proteasome inhibitors and histone deacetylase inhibitors: progress in myeloma therapeutics. Pharmaceuticals (Basel) 10(2):40. \n                    https:\/\/doi.org\/10.3390\/ph10020040","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"4052_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1346-8138.2009.00639.x","volume":"36","author":"MJ Kim","year":"2009","unstructured":"Kim MJ, Kim HO, Kim HY, Park YM (2009) Rituximab-induced vasculitis: a case report and review of the medical published work. J Dermatol 36(5):284\u2013287. \n                    https:\/\/doi.org\/10.1111\/j.1346-8138.2009.00639.x","journal-title":"J Dermatol"},{"issue":"12 Suppl","key":"4052_CR11","first-page":"ECR44","volume":"90","author":"L Pour","year":"2005","unstructured":"Pour L, Hajek R, Zdenek A, Krejci M, Krivanova A, Vorlicek J (2005) Skin lesions induced by bortezomib. Haematologica 90(12 Suppl):ECR44","journal-title":"Haematologica"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-018-4052-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4052-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-018-4052-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T01:10:24Z","timestamp":1548983424000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-018-4052-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["4052"],"URL":"https:\/\/doi.org\/10.1007\/s00520-018-4052-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,1]]},"assertion":[{"value":"5 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}